Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revive Therapeutics Ltd (OP: RVVTF ) 0.0068 UNCHANGED Streaming Delayed Price Updated: 3:57 PM EST, Nov 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Revive Therapeutics Ltd < Previous 1 2 3 4 5 6 7 8 9 10 Next > Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke November 12, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure October 31, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures September 18, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections August 28, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves July 31, 2024 Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. Via Benzinga Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure July 02, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID June 12, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product June 10, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID April 23, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product April 18, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder April 02, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID March 27, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID March 19, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Corporate Update March 12, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Explores the Use of Bucillamine for Long COVID February 01, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada January 16, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine January 10, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders December 20, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine December 18, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development November 21, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test November 06, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure October 17, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development October 11, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development August 22, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents July 28, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 July 06, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 May 30, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 May 12, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19 May 02, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 April 18, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
